BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Alan Schafer to Head Population Genetics Technologies Ltd.


5/3/2012 12:21:40 PM

Cambridge, UK – April 30, 2012 – Population Genetics Technologies Ltd., creator of innovative methods for genetic analyses and biomarker discovery, has appointed Alan Schafer, PhD to the post of Chief Executive Officer.

Schafer brings deep experience in research, “big pharma” management and building new businesses. He is Adjunct Professor of Innovation at Imperial College London Business School and was previously the Wellcome Trust’s Director of Science Funding. Before that he served as Global Vice-President of Technology Development at GlaxoSmithKline and co-founded Hexagen, a functional genomics company and subsequently acquired by Incyte. He will continue to serve on a number of research and venture capital advisory boards.

“We have validated our technology platforms and built important collaborations with world class clinical research groups and now look forward to the next phase in our development with Alan at the helm,” said Sam Eletr, a co-founder and Chairman of Population Genetics. “Our aim is to provide an efficient route for population-scale genetic analysis and biomarker discovery for application in medicine and agriculture”.

Commenting on his appointment as CEO Schafer added: “I am devoted to excellence in research and its application to improve health and human welfare and am pleased to be joining Population Genetics where the company’s talented staff, solid investor group, established capabilities and intellectual property portfolio will allow us to accelerate the application of genetics to improve human health by providing actionable information, not just sequencing data”.

Please address all inquiries to:

Dr. Frank Massam,

Chief Commercial Officer,

Population Genetics Technologies

+44 (0)1223 497359

frank.massam@populationgenetics.com

Dr Clare Jones

Account Director

Alto Marketing

+44(0)1489 557672

clarej@alto-marketing.com

About Population Genetics

Population Genetics Technologies Limited, on the Babraham Research Campus, Cambridge, UK, has developed novel approaches for genetic analyses and biomarker discovery, derived from the work of its co-founder Nobel Laureate Sydney Brenner on the rapid identification of genetic variants in large target populations. Working with researchers and clinicians the company uses its expertise and proprietary technologies to identify variation and trait association information which can then be used in the development of clinical trials, diagnostics and treatment. www.populationgenetics.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES